Copeland has entered into exclusive negotiations to purchase Dickson, a portfolio company of May River Capital and provider of environmental monitoring and cloud-native software solutions for regulated life sciences and healthcare applications.
The proposed acquisition will strengthen Copeland’s strategy of enabling an efficient and effective cold chain, building on its existing stationary and in-transit monitoring capabilities.
This will deliver an end-to-end solution that helps healthcare, pharmaceutical and life sciences customers safeguard product integrity, maintain compliance and reduce operational risk.
Quality assurance and environmental monitoring represents a large and secularly growing market opportunity, driven by increasing regulatory requirements, the expansion of biologics and cell and gene therapies, and rising demand for supply chain transparency.
Dickson's cloud-native monitoring platform, deep compliance expertise and global footprint complement Copeland's established cold chain remote services business, broadening its reach across pharmaceutical manufacturing, biotechnology, medical devices, distribution, healthcare networks and hospital systems.
Copeland CEO, Ross B. Shuster, said the deal will enhance Copeland’s ability to provide end-to-end visibility and ensure high levels of regulatory compliance through a digitally connected cold chain.
“Dickson will expand our capabilities and strengthen our ability to serve customers across every stage of the healthcare and life sciences cold chain, from pharmaceutical manufacturing through distribution and patient care,” he said.
Dickson president & CEO, Rick Weiler, said joining Copeland will allow Dickson to bring its platform and compliance expertise to a broader customer base, while continuing to invest in the technology and services customers.
The proposed transaction is expected to close in the second half of the 2026 calendar year.